Thinking to write: brain-computer interfaces that restore voice and movement

Brain-computer interfaces (BCIs) have gone in a few years from being a laboratory experiment to becoming a medical technology with real patients using it in their homes. The idea is as old as it is ambitious: to read the brain's electrical activity and translate it into digital commands, allowing people with paralysis to move a cursor, write, or control a robotic arm with their thoughts.

From early implants to patients at home

The best-known milestone is that of Neuralink, the company founded by Elon Musk, which in January 2024 implanted its first chip in a human: Noland Arbaugh, a young tetraplegic who managed to play chess and the video game Civilization VI using only his mind. Since then, the company has expanded its clinical trial and demonstrated writing speeds exceeding previous records with comparable technology.

But Neuralink is not alone. Blackrock Neurotech, Synchron, and Paradromics are working on different approaches, ranging from high-resolution flexible electrodes to sensor-based stents implanted through blood vessels, without the need to open the skull.

How the technology works

Current systems rely on electrodes that capture the signal from small populations of neurons. A machine learning algorithm then learns to associate each neural firing pattern with a movement intention.

• Invasive: electrodes inserted directly into the cortex for maximum precision.
• Less invasive: sensors placed on or inside blood vessels, with lower surgical risk.
• Non-invasive: EEG caps, with lower resolution but minimal cost.

"The ultimate goal is to restore communication and mobility to people with severe disabilities: BCI has already demonstrated thought-based writing rates that surpass the pace of conventional physical interfaces for these patients"

A growing market and accelerating regulation

The sector's figures point in a single direction. Various market analyses estimate that the BCI industry could exceed $5 billion by the mid-decade, driven by population aging, spinal cord injuries, and neurodegenerative diseases. Regulators have also spring into action: in 2024, the FDA granted breakthrough device designation to several BCI trials, and the EU is already evaluating the first devices under its medical technology regulations.

The race is also visible in the talent pipeline: laboratories such as the Wyss Center in Switzerland or academic projects funded by European grants are demonstrating that Europe wants a leading role in a field dominated by US venture capital.

Challenges and ethics

The technology still faces significant barriers: long-term biocompatibility (electrodes can degrade or trigger an immune response), signal stability over the years, and the need to replace batteries or components. Added to this is the ethical debate: neuronal privacy, informed consent for vulnerable patients, and the risk of non-medical uses, such as cognitive enhancement. Organizations like the UNESCO have already urged defining an international framework for neurotechnology before it becomes widespread.

What to expect in the coming years

The next anticipated milestones include fully wireless implants with thousands of read channels, the incorporation of sensory feedback (restoring the sense of touch to patients), and the first large-scale trials outside the hospital setting. What today allows dozens of people to communicate through thought could, within a decade, change how we interact with any digital device.

Sources

• Neuralink – Patient Registry and clinical trial updates
• Nature – High-performance brain-to-text communication
• FDA – Breakthrough Device Program
• UNESCO – Neurotechnology ethics